SCHEMBL771278

SCHEMBL771278

O=C(CCCNC(=S)NCC1CCCCC1)N1CCCC2CCCC=C21

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.34
ALDH1A1 P00352 1/20 0.34
MAPT P10636 1/20 0.34
ALOX12 P18054 1/20 0.34
HTT P42858 1/20 0.34
DPP4 P27487 6/20 0.33
ADAMTS4 O75173 4/20 0.33
ADAMTS5 Q9UNA0 4/20 0.33
CHRM2 P08172 2/20 0.33
CHRM4 P08173 2/20 0.33
CHRM5 P08912 2/20 0.33
CHRM1 P11229 2/20 0.33
CHRM3 P20309 2/20 0.33
MMP8 P22894 2/20 0.33
CACNA1G O43497 1/20 0.33
NAAA Q02083 1/20 0.33
CA12 O43570 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
MMP1 P03956 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL770888 0.97 ADAMTS4 (0.35) SMN1; SMN2ALDH1A1MAPTALOX12HTT
SCHEMBL771020 0.94 SMN1; SMN2 (0.36) SMN1; SMN2ALDH1A1MAPTALOX12HTT
SCHEMBL15377790 0.87 KMT2A (0.43) SMN1; SMN2ALOX12HTT
SCHEMBL771385 0.84 KEAP1 (0.42) SMN1; SMN2ALDH1A1CHRM2CHRM4CHRM5
SCHEMBL770270 0.84 KMT2A (0.42) SMN1; SMN2ALOX12HTT
SCHEMBL771373 0.83 KEAP1 (0.41) SMN1; SMN2ALDH1A1DPP4CHRM2CHRM4
SCHEMBL771393 0.82 KMT2A (0.41) SMN1; SMN2ALDH1A1ALOX12KEAP1NFE2L2
SCHEMBL771647 0.82 ALDH1A1 (0.46) ALDH1A1CHRM2CHRM4CHRM5CHRM1
SCHEMBL770687 0.82 PKM (0.45) SMN1; SMN2ALDH1A1MAPTALOX12HTT
SCHEMBL769979 0.80 NPC1 (0.41) SMN1; SMN2ALDH1A1ALOX12HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 SMN1; SMN2 3653/4885ALDH1A1 144/4885MAPT 618/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 SMN1; SMN2 3637/4885ALDH1A1 142/4885MAPT 638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.